Focus on Liver Cancer (HCC) Care

April 20, 2020
Donna Cryer

Advocacy Groups | <b>Global Liver Institute</b>

The COVID-19 Response Program for Patients features information tailored to the special needs of patients living with pediatric liver disease, rare liver disease, NASH, pre & post liver transplant, and liver cancer.

The effects of the novel coronavirus pandemic on liver patients’ ability to access non-COVID-19 related care have been broad and pervasive. The guidance for initiation of treatment and management for patients with viral hepatitis, transplant and cancer have been in flux during this unprecedented time of COVID for several months. In this update, I will focus on information for liver cancer patients and the efforts Global Institute is taking to help to define impactful, long term solutions.

Click here to view the full article.

Related Content:

Global Liver Institute
website logo
We Need You in The Fight Against Liver Cancer, Join #OctoberIs4Livers 2021
Global Liver Institute Applauds FDA and CDC Actions to Approve Third COVID-19 Vaccine Dose for Immunocompromised Individuals